Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseases

Saudi Mendeliome Group

Abstract

Background: To understand the contribution of Mendelian mutations to the burden of undiagnosed diseases that are suspected to be genetic in origin, we developed a next-generation sequencing-based multiplexing assay that encompasses the ~3000 known Mendelian genes. This assay, which we term the Mendeliome, comprises 13 gene panels based on clinical themes, covering the spectrum of pediatric and adult clinical genetic medicine. We explore how these panels compare with clinical whole exome sequencing (WES).

Results: We tested 2357 patients referred with suspected genetic diagnoses from virtually every medical specialty. A likely causal mutation was identified in 1018 patients, with an overall clinical sensitivity of 43 %, comparing favorably with WES. Furthermore, the cost of clinical-grade WES is high (typically more than 4500 US dollars), whereas the cost of running a sample on one of our panels is around 75–150 US dollars, depending on the panel. Of the “negative” cases, 11 % were subsequently found by WES to harbor a likely causal mutation in a known disease gene (largely in genes identified after the design of our assay), as inferred from a representative sample of 178. Although our study population is enriched for consanguinity, 245 (24 %) of solved cases were autosomal dominant and 35 (4 %) were X-linked, suggesting that our assay is also applicable to outbred populations.

Conclusions: Despite missing a significant number of cases, the current version of the Mendeliome assay can account for a large proportion of suspected genetic disorders, and provides significant practical advantages over clinical WES.

Background

The contribution of genetic variation to human diseases is an old concept, but its realization in the practice of medicine has been challenging. For most diseases, the genetic risk is both modest and strongly influenced by environmental risk factors such that the medical actionability of the identified genetic risk is limited [1, 2]. On the other hand, there are diseases that are traceable to mutations in single genes. These so-called Mendelian diseases offer a unique window into the physiological role of individual genes across tissues and stages of development [3]. From a clinical perspective, Mendelian mutations are the most medically actionable genetic variants in that they can be assigned a causal role with the attendant management and prevention benefits.

Although the first Mendelian mutation was identified in the 1980s, less than 200 Mendelian genes were known by the turn of the 21st century [4]. The publication of the human genome and the development of new analytical tools to study it, primarily next-generation sequencing (NGS), have sparked an unprecedented race to identify the suspected thousands of Mendelian genes, and as of the writing of this manuscript, more than 3000 genes are listed in the Online Mendelian Inheritance in Man (OMIM) database as disease causing [5–7]. With the discovery of each Mendelian gene, there is the immediate translational benefit of offering a precise molecular diagnosis for more patients and their families.

In order to reap the benefits of this growing knowledge of genes that cause human diseases in a Mendelian fashion, genome sequencing tools have quickly been introduced into the realm of clinical diagnostics [8]. While
sequencing of the entire genome represents the most comprehensive option, sequencing of its ~2 % coding part (whole-exome sequencing [WES]) has emerged as a cheaper and more practical alternative [9]. Application of WES in the clinic to explain the etiology of suspected Mendelian disorders has been relatively successful. A few large studies on the clinical utility of WES on a range of disorders, mostly neurological, have reported a yield of around one in four, making it the highest yield test yet in the clinical geneticist’s armamentarium [10–12].

The cost of clinical-grade WES is high, typically > US$4500 (higher when done as a child–parents trio), with a long turnaround time of three months on average. These drawbacks are primarily driven by the interpretation challenge. WES typically uncovers numerous variants, and identifying the one causal variant can be a challenge. Despite the development of several tools that aid in the automation of prioritizing WES variants, the requirement for manual inspection and expert analysis remains. In addition, there is a growing concern about the potential of WES to reveal medically actionable results that are unrelated to the original indication for the test (secondary or incidental findings) and how best to communicate them to patients [13].

An alternative approach to WES is gene panels in which an assortment of genes deemed relevant to a particular phenotype are sequenced in patients with that phenotype. Such a focused analysis of a subset of clinically relevant genes obviates or minimizes some of the key challenges described above for WES [14, 15]. One key difficulty in the design of these panels is defining the appropriate list of genes for a given phenotype owing to the remarkable variability of clinical presentations. Indeed, gene panels developed by different labs for the same indication are seldom identical and the discrepancy can be significant [16]. In this study, we took a different approach whereby we relaxed the clinical indication such that minimal clinical expertise is required to order the appropriate panel; e.g., unusual facial appearance will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel, whereas acidosis will trigger testing for the Dysmorphology/Dysplasia panel. As expected, specialties with the highest referral rate were neurology, dysmorphology, pediatric ophthalmology and immunology because of the nonspecificity of the clinical presentation, extreme and genetic heterogeneity, and because a genetic cause is highly suspected.
for a large fraction of their patient populations. Indeed, we note a relatively high yield for the respective panels of 40 %, 38 %, 52 %, and 37 % (Table 1). Specificity of the presentation appeared to bear appreciably on the clinical sensitivity of the assay. For example, with an objective evidence of skeletal dysplasia the sensitivity of the Dymorphology/Dysplasia panel was 45 % compared with 32 % when any degree of dysmorphism was used as the entry point. Similarly, the finding of a specific pattern of neurological abnormality (e.g., muscular dystrophy and neurodegenerative disorders) was associated with a much higher sensitivity compared with non-syndromic

### Table 1 Clinical sensitivities

| Gene panel type               | Total patients run | Overall clinical sensitivity | Selected subgroup clinical sensitivity                        |
|-------------------------------|--------------------|------------------------------|---------------------------------------------------------------|
| Cardiovascular                | 243                | 28 %                         | Cardiomyopathy: 32 %                                          |
|                               |                    |                              | Congenital heart disease: 10 %                               |
|                               |                    |                              | Arrhythmias: 31 %                                             |
|                               |                    |                              | Aneurysms: 29 %                                               |
| Deafness                      | 147                | 54 %                         | Hearing loss: -                                                |
| Dermatology                   | 68                 | 62 %                         | Various dermatological features: -                            |
| Dysmorphology-Dysplasia       | 354                | 38 %                         | Skeletal dysplasia: 45 %                                      |
|                               |                    |                              | Dysmorphism: 32 %                                             |
| Endocrinology                 | 36                 | 61 %                         | Pituitary and thyroid disorders: -                            |
| Gastroenterology              | 73                 | 29 %                         | Persistent jaundice: -                                        |
| Hematology                    | 33                 | 24 %                         | Aplastic anemia: -                                            |
| Inborn errors of metabolism   | 122                | 59 %                         | Metabolic disorders: -                                        |
| Neurology                     | 524                | 40 %                         | Syndromic DD/DD (recognizable syndromes): 47 %                |
|                               |                    |                              | Syndromic DD/DD NYD (not yet determined, unrecognizable)       |
|                               |                    |                              | Structural brain (cerebral/cerebellar/brain stem) and spinal malformations/anomalies: 34 %|
|                               |                    |                              | Non-syndromic DD/DD NYD (not yet determined, unrecognizable): 11 %|
|                               |                    |                              | Neurodegenerative disorders: 42 %                             |
|                               |                    |                              | Coordination/movement disorders: 69 %                         |
|                               |                    |                              | Peripheral neuropathy: 33 %                                   |
|                               |                    |                              | Myopathies/joint abnormalities: 56 %                          |
| PID                           | 196                | 37 %                         | Primary immunodeficiency disorders: -                         |
| Pulmonology                   | 36                 | 36 %                         | Chronic lung infection suspected cystic fibrosis: -           |
| Renal                         | 107                | 57 %                         | Glomerular/tubular disorders: 41 %                            |
|                               |                    |                              | Cystic kidney disease: 63 %                                   |
|                               |                    |                              | Kidney malformation: 69 %                                     |
| Vision                        | 418                | 52 %                         | Retinal dystrophy (syndromic, non-syndromic, RP, CRD, macular dystrophy, FEVR, GFS): 65 % |
|                               |                    |                              | Cataract (syndromic and non-syndromic): 34 %                  |
|                               |                    |                              | Aniridia: 33 %                                                |
|                               |                    |                              | Microphthalmia/anophthalmia (with and without coloboma): 30 % |
|                               |                    |                              | Corneal dystrophy (CHED and all other subtypes): 40 %         |
|                               |                    |                              | Others: 23 %                                                  |

**a**Primary microcephaly cases are included in this group

**b**Non-syndromic cases of autism/mental disorder and epilepsy are included under this group

**c**Ataxia cases secondary to cerebellar hypoplasia are included under the structural brain abnormalities group

**d**Cases with arthrogryposis multiplex syndromes are included under the myopathies group

CHED corneal hereditary endothelial dystrophy, CRD cone-rod dystrophy, DD developmental delay, FEVR familial exudative vitreoretinopathy, GFS Goldmann-Favre syndrome, ID intellectual disability, NYD not yet determined, PID primary immunodeficiency, RP retinitis pigmentosa
developmental delay/intellectual disability of any degree (56 % and 42 % versus 11 %). Also consistent with this is the finding that retinal dystrophies (almost always Mendelian in etiology) were more likely to have positive hits than the overall performance of the Vision panel (65 % versus 52 %).

The Mendeliome assay performs favorably compared with WES

The clinical sensitivity of our assay (43 %) is comparable to the ~25 % reported by several large clinical WES studies [10–12]. The Mendeliome assay is inherently limited to established disease genes, so it will miss cases caused by large structural variants and mutations in novel genes, although the design is flexible and allows for the addition of newly published disease genes as frequently as needed, e.g., every six months. We have queried OMIM on 30 March 2015 and found <170 OMIM genes that are not in the current design of the assay but are eligible for inclusion due to high quality of the disease link. These can be spiked into the existing two tube multiplex PCR. Even if we have to introduce these additional genes as an additional PCR (rather than spike in) for each panel, the cost of that additional PCR will be <$10 since the product will be pooled with the product of the other two tube multiplex PCR. Nonetheless, in order to assess the magnitude of this limitation, we randomly selected 213 cases that are negative by the Mendeliome assay and processed them using molecular karyotyping. Thirty-five of these were found to have likely pathogenic de novo copy number variations (CNVs) [18]. If we were to exclude these 35 cases, our clinical sensitivity would increase slightly to 44 %. The remaining 178 were processed using WES, and only 11 % (20/178) were found by WES to have a mutation in a known gene that was missed by the Mendeliome assay. Out of these 20 missed cases, the majority (n = 14, 70 %) were due to a design flaw, i.e., the disease gene was not included in the panel appropriate for the disease presentation, and this can easily be fixed by the spike-in strategy mentioned above. The remaining six cases represent limitation of the analytical sensitivity of the NGS platform we used in this study. On the other hand, we note that our cohort included two patients who had had negative diagnostic WES results prior to their enrollment in the Mendeliome assay, and were found to have likely causal mutations by the latter. These cases were missed at the interpretation phase of WES analysis and were solved by the Mendeliome assay likely because of the smaller number of variants. The much smaller number of variants to be queried by the Mendeliome assay versus WES also meant a much more rapid clinical interpretation (average 20 min per panel versus 2–3 hours per WES). This has markedly reduced the cost of interpretation on top of an already appreciable reduction in running cost (24 panel samples were run per chip versus one WES per chip). The cost is estimated to be $150 per sample with a range of $75–150 per sample depending on the panel selected. Also relevant to cost reduction is that we have had five couples who lost children with a likely recessive disease but we had no access to DNA from the deceased children. By running the appropriate panel on both parents we were able to identify the likely causal mutation at a much lower cost than the duo WES design that would have been required to reach the same conclusion. Thirty-one de novo mutations were identifiable as likely disease-causing heterozygous mutations in relevant Mendelian genes, and their de novo status was confirmed by Sanger sequencing of a single amplicon in both parents.

The Mendeliome assay expands the clinical spectrum of known genetic disorders

WES is frequently requested after one or more genes deemed relevant to the patient’s clinical presentation had been excluded by Sanger sequencing in hopes of identifying a novel genetic cause. However, many WES studies have highlighted the frequent encounter of disease-causing mutations in known genes that would not have been considered good candidates owing to the marked discrepancy between their published phenotype and the clinical presentation of the patient especially for neurological and dysmorphic disorders, which are often very heterogeneous clinically [19–21]. In a very recent study, for example, we have shown that even in familial cases that are carefully enriched for novel gene discovery by excluding all relevant candidate genes by autozygome analysis, 11 % of WES will reveal mutations in known genes missed by the enrichment step because the presentation was very atypical [22]. Indeed, in many patients with disease-causing mutations identified by the Mendeliome assay, the presentation was sufficiently different from the published phenotype of the respective gene that WES would have been pursued to establish the diagnosis (Table 2). Some of the most dramatic examples are a de novo EP300 mutation causing microcephalic primordial dwarfism, a homozygous ZNF526 mutation causing a novel Noonan-like phenotype, a homozygous IFT122 mutation causing severe ocular anomalies and unusual appendicular skeletal abnormalities, and a de novo KMT2A mutation causing genital abnormalities in an affected female, including absent uterus and vagina with remarkable clitoromegaly (Table 2). On the other hand, we have identified mutations in genes typically associated with multisystem disorders in patients with a very limited phenotype, e.g., BBS4 mutation causing isolated retinal dystrophy instead of Bardet-Biedl syndrome (Table 2). Finally, we note the highly surprising finding
| Sample ID | Gene name | Mutation | Type | Status | Origin | Type of panel | Published phenotype(s) related to the case | Observed phenotype compared with published phenotype(s) | Atypical feature(s) |
|-----------|-----------|----------|------|--------|--------|---------------|-------------------------------------------|-------------------------------------------------|-------------------|
| DG08RC00033 | FGFR2 | Missense HTZ De novo DD | Craniosynostosis syndromes | FGFR2 NM_000141.4: c.870G > C (p.Trp290Cys) | Craniofacial anomalies Sacrococcygeal tail Syndactyly Neonatal teeth (with Beare-Stevenson cutis gyrata syndrome) Choanal atresia Thinning of the genu of corpus callosum (with Pfeiffer syndrome) |
| 11DG0118 | HRAS | Missense HTZ De novo DD | Costello syndrome | HRAS NM_005343.2: c.34G > A (p.Gly12Ser) | Dysmorphic facies Corneal haziness Multiple joint dislocations Tracheomalacia and bronchomalacia |
| 10DG1851 | COL2A1 | Missense HTZ De novo DD | Spondylometaphyseal dysplasia | COL2A1 NM_033150.2: c.3023G > T (p.Gly1008Val) | Disproportionate short stature Thoracic dextroscoliosis Metaphyseal dysplasia Ingual hernia Myopia Ocular myopia Acanthosis nigricans |
| 09DG01603 | TCOF1 | Nonsense HMZ Inherited DD | Treacher Collins syndrome | TCOF1 NM_001008657.2: c.2656C > T (p.Gln886*) | Underdevelopment of zygoma Choanal atresia Microtia No external auditory meatus Malformed ossicles and semicircular canal Iris/optic disc coloboma |
| 10DG1847 | BRAF | Missense HTZ De novo DD | Cardiofaciocutaneous syndrome | BRAF NM_004333.4: c.1789C > G (p.Leu597Val) | Hypotonia Speech delay No cardiac defects Acanthosis nigricans Deep palmar and plantar creases |
Table 2 Summary of clinical features observed in the atypical cases detected by gene panel test\(^a\) (Continued)

| Sample ID | Gene | Mutation Type | Inheritance | DD | Syndrome | Clinical Features |
|-----------|------|---------------|-------------|----|----------|------------------|
| 12DG0359  | EP300| Nonsense      | De novo     | DD | None     | Atypical dysmorphic facies |
|           |      | HTZ           |             |    |          | Microcephalic primordial dwarfism |
| 11DG2179  | NFIX | Nonsense      | Unknown     | DD | Sotos syndrome type 2 | Overgrowth |
|           |      | HTZ           |             |    |          | Marfanoid habitus |
| 13DG0355  | GNS  | Frameshift    | Inherited   | DD | Mucopolysaccharidosis type IId | Mild coarse face |
|           |      | HTZ           |             |    |          | Advanced RP |
| 11DG2478  | COL11A2| Missense | Inherited | DD | Otospondylomegaepiphyseal dysplasia | Epiphyseal dysplasia |
|           |      | HTZ           |             |    |          | Hypoplastic optic nerve |
| 14DG1212  | IFT122| Splice site   | Inherited   | DD | Cranioectodermal dysplasia 1 | Nystagmus |
|           |      | HTZ           |             |    |          | Iris and optic nerve coloboma |
|           |      |               |             |    |          | Microphthalmia |
|           |      |               |             |    |          | Duplicated thumb and big toe |
|           |      |               |             |    |          | Post-axial polydactyly |
| 10DG0615  | CNNM4| Missense      | Parents not tested | DD | Robinow syndrome | Vertebral anomalies (in Robinow syndrome) |
|           |      | HTZ           |             |    |          | Atypical fibrochondrogenesis-like skeletal dysplasia |
| 12DG0398  | BBS4 | Frameshift    | Compound De Novo | DD | Bardet-Biedl syndrome 4 | Dysmorphic facies |
|           |      | HTZ           |             |    |          | Absent uterus and vagina, remarkable clitoromegaly |
|           |      |               |             |    |          | No overgrowth |
|           |      |               |             |    |          | Retinal coloboma |
|           |      |               |             |    |          | No dental anomalies |
|           |      |               |             |    |          | Lack of other features of BBS |

\(^a\) Saudi Mendelianome Group Genome Biology (2015) 16:134
Table 2 Summary of clinical features observed in the atypical cases detected by gene panel test\(^a\) (Continued)

| Case# | Gene | Mutation Type | Mutation Details | Clinical Findings |
|-------|------|---------------|------------------|-------------------|
| 14DG0073 | ATRX | Nonsense | Hemizygous | Inherited | Neuro | Mental retardation-hypotonic facies syndrome, X-linked | Microcephaly | RP |
| 12DG1296 | ALMS1 | Frameshift | HMZ | Inherited | Vision | Alstrom syndrome | Optic disc coloboma |
| 12DG1554 | STXBP1 | Missense | HTZ | De novo | Neuro | Epileptic encephalopathy, early infantile, 4 | Seizures |
| 13DG1051 | CDX5 | Nonsense | HMZ | Inherited | Neuro | Epileptic encephalopathy, early infantile, 2 | GDD |
| 10DG2024 | GTDC2 | Missense | HMZ | Inherited | Neuro | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8) | None |
| 12DG0133 | HSD17B4 | Missense | HMZ | Inherited | Neuro | D-bifunctional protein deficiency | Neonatal seizures |
| 10DG0415 | ATN1 | Missense | HTZ | De novo | Neuro | Dentatorubro-pallidolysian atrophy | None |
| 12DG0705 | KIAA0196 | Missense | HTZ | De Novo | Neuro | Ritscher-Schinzel syndrome | Seizures |
| 10DG0351 | ADRA2B | Nonsense | HMZ | Inherited | Neuro | Non-syndromic ID | None |
| 12DG0532 | ZNF526 | Missense | HMZ | Inherited | Neuro | Mild non-syndromic ID | None |
| 14DG0745 | WDR45B | Nonsense | HMZ | Inherited | Neuro | ID and microcephaly | Primary microcephaly |

\(^a\) Saudi Mendeliome Group Genome Biology (2015) 16:134
Table 2 Summary of clinical features observed in the atypical cases detected by gene panel test\(^a\) (Continued)

| 13DG2156 | WDR81 | Nonsense | HMZ | Inherited | Neuro | Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2 | Cerebellar hypoplasia | Normal corpus callosum | Prenatal onset complicated by neonatal death |
|----------|-------|----------|-----|-----------|-------|-------------------------------------------------|---------------------|------------------------|---------------------------------------------|
| NM_152348.3: c.133C > T (p.Gln45*) |       |          |     |           |       |                                                  |                     |                         |                              |

\(^a\) Atypical case is defined as a case that has unusual clinical features, unusual mode of inheritance, a novel phenotype or lack of typical features

AD, autosomal dominant, AR, BBS Bardet-Biedl syndrome, DD DYSMORPHIA-DYSPLASIA panel, FTT failure to thrive, GDD global developmental delay, HMZ Homozygous, HTZ Heterozygous, ID intellectual disability, LCA, Leber congenital amaurosis, MR, MRI magnetic resonance imaging, PVL, Periventricular leukomalacia, RP retinitis pigmentosa, TR, Tricuspid regurgitation
of a homozygous nonsense mutation in TCOF1 causing severe Treacher-Collins syndrome while the carrier parents are completely normal clinically. Interestingly, this mutation had been missed by direct Sanger sequencing of TCOF1, most likely because the expectation was a heterozygous peak on the sequence chromatogram given the dominant nature of the disease. This is the first instance of a recessive inheritance of TCOF1.

**Improved annotation of the human variome**

Large scale genomic studies offer opportunities to improve the annotation of the human variome. This study, in which more than 2300 well phenotyped human patients in a highly consanguineous population have been specifically tested for established disease genes, offers several advantages. First, we were able to confirm genes that were only considered candidates because their candidacy was based on single mutations/families so their status based on this study should be upgraded in OMIM as such (e.g., ARL14EP, ZNF526, WDR45B, and WDR81). Second, we have added 433 novel disease alleles from a total of 788 variants, the largest to be reported in a single study (Additional files 1 and 2). Interestingly, 22 variants were concurrently added to the Human Gene Mutation Database (HGMD) after submission of the manuscript. These are in the HGMD release of 2015 and not in that of 2014. Third, the very large number of variants we identified in the course of this study represent an unprecedented resource on the Arab variome (nearly all patients in this study were Arab in ethnicity), and this will be invaluable to the interpretation of clinical molecular genetic tests on Mendelian genes in Arab patients since it will help address the uncertainty surrounding the identification of many Arab-specific or Arab-enriched variants (Additional file 1). Fourth, the high degree of consanguinity allowed us to observe many variants in homozygosity as a result of autozygosity. This is particularly helpful when these variants were previously reported as disease-causing because observing them in the homozygous state at a relatively high population frequency strongly argues against their purported disease link. Additional file 3 includes 342 HGMD variants that appeared at high frequency (minor allele frequency [MAF] >1 %) in our in-house database, including 133 variants with MAF >5 %. Of these variants with MAF >1 % in our cohort, 137 are listed in the 1000 Genomes Project with a MAF <1 %, highlighting the unique distribution of variants in our population and the value it adds to the annotation of the human variome. Furthermore, our finding of previously reported disease genes that harbor apparently inactivating mutations in the homozygous state at a relatively high frequency and in patients who lack the purported phenotype challenges their listing as disease genes (e.g., CACNA1F, MYH8, and PRX1) although we acknowledge a potential role of such confounding factors as reduced penetrance.

**Discussion**

Genomics have ushered in a new era for clinical medicine [23]. The ability to scan the entire genome (or its coding part) for disease-causing mutations relatively free of clinical bias has uncovered the limited sensitivity and specificity of making diagnoses on clinical grounds only. This was first apparent with the advent of array comparative genomic hybridization, which specifically targets large genomic mutations. Subsequently, whole genome sequencing (WGS) and WES confirmed the same pattern. This raises the interesting question of whether all patients with a suspected genetic diagnosis should have WGS/WES as the initial diagnostic test [24]. Pending data on the validity of this approach, one has to consider some practical challenges. Cost remains a significant hurdle that prevents most patients, especially in less wealthy countries, from accessing WGS/WES. While the running cost will continue to decrease, the challenge of identifying a single causal variant from among tens of thousands will remain formidable for the foreseeable future [25]. In addition, debate still rages over the issue of incidental findings, with changing guidelines reflecting the strong and sound arguments made by camps on either side of the debate, especially in pediatrics [26–28]. Gene panels that specifically target a disease relevant to the patient’s presentation appear to address some of these limitations but suffer from lack of uniformity in design and are typically too focused on a particular phenotype such that they may miss atypical presentations.

In this study, we sought to develop an assay that addresses the above-mentioned limitations. In the design stage, we limited ourselves to genes that are very likely to be disease-causing in a Mendelian context based on the best available evidence in order to eliminate the uncertainty surrounding the finding of variants in genes not known to be linked to human diseases. We mainly included genes whose pathogenicity was supported by the presence of two pathogenic alleles. However, exceptions were made for genes with a single reported mutation but are further supported by compelling mouse data or positional mapping data. This is important because it has to be acknowledged that clinical WGS/WES currently appears to saddle the divide between clinical care and research [29]. If the Mendeliome assay is negative, it may be easier to prepare the patient for the possibility of identifying a novel genetic cause by WGS/WES that requires confirmation in a research setting. Unlike currently available gene panels, we sought to be as inclusive as possible to minimize the challenge of atypical cases. For example, a gene for myopia presenting with ectopia lentis would still be identified because virtually
every gene known to present with a prominent eye phenotype was included in the Vision panel [30]. Indeed, our analysis showed that only 3 % (62/2,357) of cases may have been missed because the gene was not included in the right panel and even this limitation can be addressed through the spike-in design. Such broad and inclusive design was particularly helpful in disease categories that are characterized by very high rates of heterogeneity. In addition to the Vision panel, we also note the high rate of atypical cases identified by the Dysmorphology/Dysplasia, Neurology and Immunology panels, although such cases were encountered in nearly all the panels.

Conclusions
Our design brought about a dramatic reduction in cost both in terms of reagents and interpretation. Although clinical WES/WGS with exceptionally rapid turnaround time has been reported, those were exceptional scenarios that required a level of infrastructure and logistics well beyond a typical healthcare facility [31]. On the other hand, our turnaround time (one week from receiving the sample to calling the candidate variants and three days to confirm the variants by Sanger) can be offered routinely as a service to any healthcare provider. Therefore, our test can be viewed as a potential first tier test that is relatively inexpensive and rapid with a straightforward consenting process. If negative, a more comprehensive genomic test can be ordered as a second-tier test such that the higher order complexities (cost, consent, etc.) associated with this test can be confined to a smaller number of individuals than it would otherwise be if it were offered as a first-tier test.

Materials and methods
Human subjects
All families were enrolled under several King Faisal Specialist Hospital and Research Centre institutional review board-approved protocols (depending on the phenotype), after signing a written informed consent. These included: “Genetics of vision impairment in Saudi Arabia” (RAC# 2070 023 Research Advisory Council), “Genetics of craniofacial birth defects” (RAC# 2080 006), “Characterization of peroxisomal biogenesis disorders in Saudi Arabia” (RAC# 2080 033), “Genetics of OI in Saudi Arabia” (RAC# 2090 035), and “Study of Mendelian phenocopies of common diseases” (RAC# 2121 053). The study was carried out in accordance with the declaration of Helsinki.

Defining the Mendeliome
Patients with various hereditary disorders most often are referred to the medical geneticist either through their primary care provider or through a medical subspecialist who attended to the most prominent clinical presentation (i.e., neurological, ophthalmology, skin, renal, hematological, etc.). Therefore, we sought to design our symptom/sign-based gene panels, collectively known as the “Mendeliome” in a way that simulates the way these patients present in clinical practice to the respective specialty. Mendelian disorders are defined as hereditary disorders caused by a single autosomal or X-linked gene. The OMIM database, which currently contains about 4300 monogenic disorders associated with known molecular defects, represents the most comprehensive source of such information on monogenic disorders. Therefore, it was used as the primary source for gene identification. However, it was manually curated to ensure that only genes with confirmed links to disease are included. It was also supplemented with additional data from PubMed, the Genetic Testing Registry, and Gene Tests. As such, 13 gene panels which cover the spectrum of “pediatric and adult” clinical genetic medicine were constructed. Within each panel, genes were sorted based on the most prominent sign/symptom with which they are most likely to be associated upon presentation to clinical care. This presentation may help the referring clinician, and without requiring sophisticated knowledge about these genes, decide on the appropriateness of genetic testing using these gene panels. Since many genetic disorders are as likely to present to several medical specialties, we allowed for redundancy between the different panels (average 15 %) such that a gene may be present in more than one panel.

Primer design and multiplexing assay development
We used 3070 genes covering over 4,000 Mendelian disorders as annotated by OMIM up to August 2013 as a basis for the design and synthesis of highly multiplexed gene panels using Ion AmpliSeq Designer software (Life Technologies, Carlsbad, CA, USA). Additional file 4 displays the list of genes, their corresponding panels, information about the used transcripts, physical positions, and number of exons. Of these 3070 genes, 2826 are already listed in the Genetic Testing Registry. Thirteen panels encompassing nearly all of the OMIM genes were defined broadly based on clinical disciplines with some redundancy in gene content of individual panels. Primer design was based on generating amplicons with an average length of 200 bp providing 90 % minimum coverage of the coding DNA sequence, and, on average, 10 bp flanking regions of associated exons. Additional file 5 contains all AmpliSeq primers used in the assay. Following in silico design, coverage was assessed for compliance with design criteria and manual processes applied on a gene by gene basis to ensure adequate coverage and resolve factors such as 3’ SNPs that could impact
primer efficiency. Primers for each panel were then synthesized and pooled into two multiplex reactions based on PCR compatibility minimizing likelihood of primer–primer interactions. Following synthesis, primer pools were tested for coverage, recommended multiplexing and other quality control metrics to ensure specifications were met. Panels ranged from 96–758 genes with >90% coverage in 97–100% of genes in each panel. Additional file 6 shows information about the different panels and related design information.

Library preparation and NGS
DNA samples (10 ng of each) were treated to obtain the Ion Proton AmpliSeq library for one of the 13 gene panels as appropriate. DNA was amplified using gene panel Primer Pools, AmpliSeq HiFi mix (Thermo Fisher, Carlsbad, CA, USA) and 10–15 amplification cycles. PCR pools for each sample were combined and subjected to primer digestion with FuPa reagent (Thermo Fisher, Carlsbad, CA, USA). Pooled amplicons were then ligated with universal adapters. After purification, libraries were quantified by quantitative PCR and normalized to 100 pM. Normalized libraries were barcoded (ligated with 24 different Ion Xpress Barcode adapters) and pooled in equal ratios for emulsion PCR (ePCR) on an Ion OneTouch System. Following ePCR, templated Ion Sphere particles were enriched using the Ion OneTouch ES enrichment system enrichment system. Both ePCR and enrichment procedures followed the manufacturer’s instructions (Thermo Fisher, Carlsbad, CA, USA). The template-positive Ion PI Ion Sphere particles were processed for sequencing on the Ion Proton instrument (Thermo Fisher, Carlsbad, CA, USA).

Data processing and bioinformatics analysis
The data of each run were analyzed through a multistep pipeline. Additional file 7 summarizes the analysis workflow (pipeline), and the details of the variant filtration sub-pipeline. The left side of Additional file 7 demonstrates the basic steps of our variant detection workflow. In the first step of this pipeline, the quality of the reads is verified and regions of the reads with low quality (less than 20) are trimmed out before alignment. The runs with low yield after this quality check are excluded. Additional file 8 shows the quality data for the runs per panel at both Q0 and Q17 (results per panel is the average for all samples in the panel). In the second step, the reads are aligned to the reference hg19 sequence. The alignment program was tmap, which is distributed within the Ion Torrent Suite (Thermo Fisher, Carlsbad, CA, USA) [32]. Additional file 9 shows statistics about the alignment and coverage related to the target regions as well as the observed depth per panel (results per panel is the average for all samples in the panel). In the second step, the reads are aligned to the reference hg19 sequence. The alignment program was tmap, which is distributed within the Ion Torrent Suite (Thermo Fisher, Carlsbad, CA, USA) [32]. Additional file 9 shows statistics about the alignment and coverage related to the target regions as well as the observed depth per panel (results per panel is the average for all samples in the panel). The observed depth after alignment ranges from 162× (for the Neurology panel including 758 genes) to 840× (for the Renal panel including 96 genes). It can be observed from Additional files 8 and 9 that the data are of good quality and the observed depth is very close to the expected depth. We can also conclude that it is possible to

| Panel                          | Input | Functional sites | Public Pop. DBs | SGP Pop. DB | Quality | Zygosity |
|-------------------------------|-------|-----------------|-----------------|-------------|---------|----------|
| Cardiovascular                | 746   | 338             | 76              | 26          | 9       | 2        |
| Deafness                      | 828   | 257             | 63              | 50          | 17      | 6        |
| Dermatology                   | 1113  | 271             | 71              | 41          | 17      | 5        |
| Dysmorphology/Dysplasia       | 1529  | 369             | 80              | 43          | 15      | 2        |
| Endocrinology                 | 1129  | 326             | 61              | 42          | 19      | 5        |
| Gastroenterology              | 362   | 190             | 60              | 20          | 6       | 1        |
| Hematology                    | 1474  | 324             | 79              | 39          | 18      | 3        |
| Inborn Errors of Metabolism   | 1955  | 571             | 94              | 54          | 24      | 4        |
| Neurology                     | 2885  | 718             | 158             | 87          | 29      | 4        |
| PID                           | 633   | 309             | 111             | 22          | 6       | 1        |
| Pulmonology                   | 723   | 230             | 74              | 39          | 21      | 3        |
| Renal                         | 507   | 132             | 35              | 21          | 7       | 1        |
| Vision                        | 906   | 341             | 75              | 51          | 17      | 3        |
| Total (averages)              | 1138  | 337             | 80              | 41          | 16      | 3        |

The table entries are the average number of variants per panel after applying the respective filter in the column title. The column titled ‘Input’ is the input without applying any filter. The column titled ‘Functional sites’ is for the step of filtering intronic, UTR, synonymous variants. The column titled ‘Public Pop. DBs’ is for the step of filtering variants based on the 1000 Genomes Project database. The column titled ‘SGP Pop. DBs’ is for the step of filtering variants based on the in-house database. The column titled ‘Quality’ is for the step of filtering based on the quality criteria. The column titled ‘Zygosity’ is for the step of excluding non-homozygous variants.
increase the number of samples multiplexed per chip for panels with low numbers of genes, such as the Renal and Pulmonary panels, which reduces the cost without affecting the quality. In the third step, the aligned reads were processed for variant calling using the Torrent Suite Variant Caller (TVC) program, which is tuned to Ion Torrent data and considers quality scores and manufacturer-specific details. In the subsequent step, the variants are annotated using public knowledge databases as well as in-house variant databases, using in-house programs that extend the public Annovar package. The public databases include those available from the Annovar package and other commercial datasets like HGMD [33]. The in-house databases include collections of disease-causing variants published by different Saudi teams and aggregation of the variants produced by the samples in this paper. In the final step of the pipeline, the non-relevant variants are filtered out based on their functional characteristics and their abundance in our datasets. The right side of Additional file 7 illustrates the details of the variant filtering process. Variants that are less likely to play a functional role (intronic and synonymous) and variants that were present in population databases (e.g., in the 1000 Genomes Project database with MAF >1 %) are filtered out. Furthermore, variants that are frequent in our in-house database are also filtered out; a variant with more than 20 occurrences were considered frequent. (The cutoff of 20 occurrences has been selected on test data to assure 100 % sensitivity.) An individual base quality of 100 (using Phred-like score produced by the Torrent Suite base caller) is also selected to exclude low confident variants. The few remaining variants are then analyzed based on relevance of gene to phenotype, zygosity (when indicated), and SIFT and PolyPhen scores (for missense variants). Table 3 shows the efficiency of our filtering strategy. It shows that the subsequent filtering steps lead to a short list of variants to be examined by domain experts. As the tables show and as expected, the larger the panel, the larger the list. It is also important to note that having more samples included in the in-house database leads to more filtration power and makes the list even shorter. Ultimately, the recognized causal variant is identified as pathogenic or likely pathogenic as defined by the recent American College of Medical Genetics and Genomics (ACMG) guidelines ("Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology"), and the extensive variant data obtained by sequencing thousands of ethnically comparable patients (Saudis) was helpful in applying population frequency as a reliable criterion for pathogenicity in this study.

**Molecular karyotyping**

Given that the Mendeliome assay is inherently limited to established disease genes and will miss cases caused by large structural variants, we randomly selected 213 cases that are negative by the Mendeliome assay and processed them using molecular karyotyping. The CytoScan HD (Affymetrix) array was used for the majority of our patients. This array platform contains 2.6 million markers for CNV detection (Affymetrix), of which 750,000 are genotype SNPs and 1.9 million are nonpolymorphic probes, for the whole genome coverage. The analysis was performed using the Chromosome Analysis Suite version Cyto 2.0.0.195(r5758). Oligonucleotide probe information is based on build 37 of the UCSC Genome Browser (GRCh37/hg19) [34].

Briefly, 250 ng of genomic DNA was digested with the restriction enzyme NspI and then ligated to an adapter, followed by PCR amplification using a single pair of primers that recognized the adapter sequence. The PCR products were run on a 2 % Tris-borate-EDTA (TBE) gel to confirm that the majority of products were between 150 and 2000 bp in length. To obtain a sufficient quantity of PCR product for further analysis, all products from each sample were combined and purified using magnetic beads (Agencourt AMPure, Beckman Coulter, Beverly, MA, USA). The purified PCR products were fragmented using DNase I and visualized on a 4 % TBE agarose gel to confirm that the fragment sizes ranged from 25 to 125 bp. The fragmented PCR products were subsequently end-labeled with biotin and hybridized to the array. Arrays were then washed and stained using a GeneChip Fluidics Station 450 and scanned using an Affymetrix GeneChip Scanner 3000 7G. Scanned data files were generated using Affymetrix GeneChip Command Console Software (version 1.2) and analyzed with the Chromosome Analysis Suite.

The hidden Markov model available within the Chromosome Analysis Suite software package was used to determine the copy-number states and their breakpoints. Thresholds of log2 ratio ≥0.58 and ≤–1 were used to categorize altered regions as CNV gains (amplification) and copy number losses (deletions), respectively.

To minimize the detection of false-positive CNVs arising due to inherent microarray "noise", only alterations that involved at least 50 consecutive probes and that were at least 500 kb in size were used to categorize altered regions as CNV gains (amplification), whereas those at least 200 kb in size were used to categorize copy number losses (deletions).

We then proceeded to evaluate the CNVs detected in our patients based on the ACMG standards and guidelines. The genic content in the CNV interval of all the patients who had a molecular karyotype performed was taken into consideration by seeking recent publications
to compare breakpoints, phenotypes, and different sizes of CNVs that overlapped. To exclude aberrations representing common benign CNVs, all the identified CNVs were compared with those reported in the Database of Genomic Variants [35] and those reported in our in-house database for individuals who have been classified as normal.

De novo CNVs that met the size cutoff of 200 kb for deletions and 500 kb for duplications (based on the laboratory’s consideration of the performance characteristics of the assay used) and were not found in either parent were classified as pathogenic. However, this does not eliminate the possibility that pathogenic CNVs exhibiting incomplete penetrance or variable expressivity can be present in an unaffected parent.

Whole exome sequencing and analysis
The remaining 178 were processed using WES. Each DNA sample (100 ng) was treated to obtain the Ion Proton AmpliSeq library. Briefly, DNA was amplified in 12 separate wells using Exome Primer Pools, AmpliSeq HiFi mix (Thermo Fisher, Carlsbad, CA, USA) and ten amplification cycles. All 12 PCR pools were combined in one well and subjected to primer digestion performing incubation with FuPa reagent (Thermo Fisher, Carlsbad, CA, USA). Amplified exome targets were ligated with Ion P1 and Ion Xpress Barcode adapters. After purification libraries were quantified using quantitative PCR with the Ion Library Quantification Kit (Thermo Fisher, Carlsbad, CA, USA). The prepared exome library was further used for emulsion PCR on an Ion OneTouch System and templated Ion Sphere particles were enriched using Ion OneTouch ES, both procedures following the manufacturer’s instructions (Thermo Fisher, Carlsbad, CA, USA). The template-positive Ion P1 Ion Sphere particles were processed for sequencing on the Ion Proton instrument (Thermo Fisher, Carlsbad, CA, USA). Approximately 15–17 Gb of sequence was generated per sequencing run. Reads were mapped to UCSC hg19 [36] and variants identified using the Saudi Human Genome Program (SHGP) pipeline.

Availability of data
All the variants generated on the participants of this study, including disease and non-disease causing mutations from the gene panels and from WES data, are accessible through the Saudi Variome Database [37, 38]. Tabulated versions of the data are provided in Additional files 1, 2, 3, 4, 5, 6, 8, and 9 and can be accessed through [37, 38]. The exome files can be accessed through [37, 38]. The ClinVar accession numbers for the novel variants in this paper are SCV000221340–SCV000221740.

Additional files

**Additional file 1:** Table S1. List of unique variants that are disease-causing.

**Additional file 2:** Table S2. List of novel variants.

**Additional file 3:** Table S2. Frequent variants encountered in our study that are designated as disease-mutation by HGMD. This table includes 342 HGMD variants that appeared at high frequency (MAF >1 %) in our in-house database. Of these, 133 variants appeared at MAF >5 %. We also observe that the MAF of 137 of them in the 1000 Genomes database is less than 1 %. We also compared the HGMD release of 2013 with that of 2014. We found that in the 2014 release of HGMD, there are 16 new variants with MAF >5 %.

**Additional file 4:** Table S7. List of genes included in the Mendeliome assay.

**Additional file 5:** Table S8. Gene panel primers – contains all AmpliSeq primers used in the assay.

**Additional file 6:** Table S9. Gene panel design information.

**Additional file 7:** Figure S1. Variant detection and analysis workflow. On the left side we show the basic steps of our variant detection workflow. The base calling step involves the transformation of signal data into base space (A/C/G/T). The output of this step is an unaligned reads in BAM format. The mapping is the process of aligning the reads to the reference human genome (hg19). The output of this step is alignments of all reads (BAM format). The variant calling involves the detection of variations in the aligned reads. The variant filtration step involves the exclusion of variants not related to the disease. On the right side, we show the details of the variant filtration workflow. The first step involves the exclusion of deep intronic variants (more than 20 bases far from the exon terminals), UTRs, and non-frameshift indels. Then variants that are frequent in public databases (the 1000 Genomes database) with MAF >1 % are excluded. Variants that are also frequent in our in-house database are also excluded (MAF >1 %). The remaining variants are then filtered based on a score (>100) computed by Torrent Suite according to different criteria like confidence of base calls, depth, and context bases. The final step involves filtering based on zygosity (if the variant is homozygous). Then domain experts evaluate the variants based on their knowledge about the phenotype. The remaining short list of variants (if not empty) is then sent to the Sanger team to validate the variants. The numbers next to each step in the filtration is the average number of the remaining variants after applying the next filtering step.

**Additional file 8:** Table S5. Sequencing quality data for the runs per panel (entries are the average of all runs per panel).

**Additional file 9:** Table S6. Read alignment quality per panel (entries are the average of all reads per panel).

Abbreviations
ACMG: American College of Medical Genetics and Genomics; bp: base pair; CNV: copy number variation; ePCR: emulsion PCR; HGMD: Human Gene Mutation Database; MAF: minor allele frequency; NGS: next-generation sequencing; OMIM: Online Mendelian Inheritance in Man; PCR: polymerase chain reaction; SNP: single nucleotide polymorphism; TBE: Tris-borate-EDTA; UTR: untranslated region; WES: whole exome sequencing; WGG: whole genome sequencing.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors contributed to the collection and analysis of data. All authors read and approved the final manuscript.

Acknowledgement
This study was supported by a research grant from King Salman Center for Disability Research (FSA) as well as the Saudi Human Genome Project initiative, KACST. Saudi Mendeliome Group (alphabetical order): Abdulwahab, Firdous; Abouelhoda, Mohamed; Abouthuraya, Rula; Abumansour, Imran; Ahmed, Syed O.; Al Rubeaan, Khalid; Al Tassan, Nada; AlAbdulaziz, Basma;
AIAbdulrahman, Khalid; Alamer, FH; Alzamari, Ana; Al-Raeei, Lina A; Alldanemesh, Mohammad; Al-Dhekriti, Hasan; AlDuseyy, Haya; Alqadzani, Sulaiman; Al-Ghonaum, Abdulaziz; Alhamed, Mohammad; Alshammar, Amal; Alhissi, Safa Ahmed; Alissa, Abdulkefah; Aljurf, Mahmoud D; Alkunayr, Fowzan S; Alkunayr, Hisham; Allam, Rabab; Almarsharawi, Iman; J Almasheesher, Agaidd; AlMostaafa, Abbe; Al-Mousa, Hamoud; Al-Muhsen, Sadeh; Almutaawi, Eid A; Alnader, Noukhra; Alqaeb; Ehelekha; ALOtaiabi, AB; Alotibi, Afeef; Al-Sartah, Sarah; Al-Saud, Bandar; Al-Saud, Haya; Alshahammit, M; Alsharif, Hadeel; Alshikul, Abdulmoneem H; Al-Sulaiman, Ayman; Altamimi, AS; Al-Tayeb, Hansa; Alwaalade, SM; Al-Younes; B; Alzahrani, Fatima; Anazi, Shams; Arnaout, Rand; Bhashi, Fahad; Binamer, Yousef; Binhamuid, FA; Boholea, Saeed; Broeirig, Dieter; Budelski, Martin; Dasouki, Majed Jamal; Damiri, Nidunia Francis; Elmarin, Tazin; El-Kaloby, Mohamed; Elsayer, Hussien; Faqiel, Eissa; Faqih, Tarig; Hafic, Sabaya Haig; Abdulrahman, A; Hashem, Mais; Hawawri, Abbass; Hazzaa, Selwa; Ibrahim, Nirmi; Imtiaz, Faiaq; Jabr, Amal; Kattan, Rana; Kaya, Namik; Kentab, Amal; Khalif, Dana; Khan, Arif; Khier, Omnia; Meyer, Brian; Mohamed, Jawahir; Monies, Dorota; Mulya, Paul N; Musat, Hatem; Naim, EA; Owaad, Tarek; Patel, Nisha; Ramzan, Khushnoooda; Saleh, Mustafa A; Shagranri, Mohammad; Shaheen, Ranad; Shamseldin, Hanan; Sogaty, Sameera; Subhani, Shazia; Taibah, Khalid; Waki, Salma M.

Received: 14 February 2015 Accepted: 12 June 2015

References

1. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:743–53.

2. Atia J, Ioannidis JP, Thrakkinian A, McEvoy M, Scott RJ, Minelli C, et al. How can we approach an article using genetic association? C. What are the results and will they help me in caring for my patients? JAMA. 2009;301:304–8.

3. Antonarakis SE, Beckmann JS. Mendelian disorders deserve more attention. Nat Rev Genet. 2013;14:415–23.

4. Peltonen L, McKusick VA. Dissecting human disease in the postgenomic era. Science. 2001;291:1224–9.

5. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 2001;285:540–4.

6. Lupski JR, Reid JG, Gorzaga-Jauregui C, Rio Deilos D, Chen DC, Nazaret L, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;362:1181–91.

7. Choi M, Scholl UJ, Ji W, Liu T, Tikhonova IR, Zumbo P, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. 2009;106:19096–101.

8. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013;15:259–67.

9. Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet. 2010;19:R145–51.

10. Yang Y, Muzny DM, Reid JG, Bainbridge MN, Ward PA, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med. 2013;369:1502–11.

11. Lee H, Delignan J, Dorrani N, Stroom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare mendelian disorders. JAMA. 2014;312:1870–7.

12. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1970–9.

13. Kitzman R, Appelbaum PS, Chung W. Return of secondary genomic findings vs patient autonomy: implications for medical care. JAMA. 2013;310:696–700.

14. Katsanis SH, Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet. 2013;14:415–23.

15. Rehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet. 2013;14:925–30.

16. Xue X, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med. 2015;17:444–51.

17. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 2012;13:341.

18. Al-Gattan SM, Wakil SM, Anazi S, Alzamari AM, Patel N, Shaheen R, et al. The clinical utility of molecular karyotyping for neurocognitive phenotypes in a consanguineous population. Genet Med. 2014. 10.1038/gim.2014.184

19. Need AC, Shiavi V, Hitomi Y, Schook K, Shanna KV, McDonald MT, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet. 2012;49:353–61.

20. Foo J-N, Liu J-J, Tan E-K. Whole-genome and whole-exome sequencing in neurological diseases. Nat Rev Neurol. 2012;8:508–17.

21. Singleton AB. Exome sequencing: a transformative technology. Lancet Neurol. 2011;10:942–6.

22. Alzamari Anas M, Patel N, Shamseldin Hanan E, Anazi S, Al-Dosari Mohammed S, Alzahrani F, et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiple consanguineous families. Cell Rep. 2015;10:48–61.

23. Green ED, Geyser M, Institute NHGR. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470:204–13.

24. Soden SE, Saunders CJ, Willig LF, Farrow EG, Smith LD, Petrkin JE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168–8.

25. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, Chab H, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA. 2014;311:335–45.

26. Ross LF, Rothstein MA, Clayton EW. Mandatory extended searches in all genome sequencing: “Incidental findings”, patient autonomy, and shared decision making. JAMA. 2013;310:367–8.

27. Christenhusz GM, Devriendt K, Dierick K. Tell or not to tell? A systematic review of ethical reflections on incidental findings arising in genetics contexts. Eur J Hum Genet. 2012;20:248–55.

28. Abdul-Karim R, Berkman BE, Wendler D, Rid A, Khan J, Badgett T, et al. Disclosure of incidental findings from next-generation sequencing in pediatric genomic research. Pediatrics. 2013;131:656–71.

29. Green ED, Geyser M, Institute NHGR. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470:204–13.

30. Saunders CJ, Miller NA, Soden SE, Dinwiddie DL, Noll A, Shaheen R, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med. 2012;4:154ra135–5.

31. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164–4.

32. Human Genome Browser. http://genome.ucsc.edu/cgi-bin/hgGateway.

33. Database of Genomic Variants. http://projects.tcag.ca/variation/.

34. Human Genome Browser. http://genome.ucsc.edu/.

35. Mendliome Variants Database. http://shsg.ksu.edu/sbioinf/dbv/dbvariants/mendliome/.

36. Saudi Human Genome Program. http://shsg.kacst.edu.sa/bioinf/dbv/dbvariants/mendliome/.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit